T

Tenpoint Therapeutics

Engineered cell therapies to restore vision

Overview

TenPoint Therapeutics develops regenerative therapies for eye diseases. Its main approach is engineered cell-based therapeutics and in vivo reprogramming to replace damaged retinal or ocular tissue and potentially restore vision with a single, long-lasting treatment. Unlike many groups that work on generic regenerative methods, TenPoint focuses on the eye’s unique environment to direct therapies and reverse disease progression. The company aims to bring these regenerative solutions to patients by partnering with healthcare providers, with the ultimate goal of restoring sight and improving quality of life. The founding team comes from leading ocular research centers, giving them deep expertise in regenerative biology and translational medicine.

Significant Headcount Growth

Work here?Claim your company

About Tenpoint Therapeutics

Simplify's Rating
Why Tenpoint Therapeutics is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

51-200

Company Stage

Series B

Total Funding

$305M

Headquarters

London, United Kingdom

Founded

2020

Get referred to Tenpoint Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • The January 28, 2026 FDA approval unlocked immediate U.S. commercialization and nationwide availability.
  • Tenpoint raised $235 million on January 28, 2026, funding launch, inventory, and expansion.
  • The November 9, 2026 telehealth program broadens access and should lift prescription conversion.

What critics are saying

  • Tenpoint depends almost entirely on YUVEZZI; a launch stumble cripples the company.
  • Presbyopia patients still buy readers; low repeat use can suppress long-term YUVEZZI demand.
  • UK and EU approvals remain pending after July 13, 2026; setbacks delay expansion revenue.

What makes Tenpoint Therapeutics unique

  • YUVEZZI became the first dual-agent presbyopia eye drop on January 28, 2026.
  • Tenpoint bundles telehealth, direct-to-patient delivery, and retail pharmacy access for YUVEZZI.
  • Lupin's August 20, 2026 partnership extends YUVEZZI commercialization across Europe.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$305M

Above

Industry Average

Funded Over

3 Rounds

Series B funding is typically for startups that have proven their business model and need more funding to expand rapidly—often by entering new markets or adding more products. Investors are usually venture capital firms that specialize in later-stage investments.
Series B Funding Comparison
Above Average

Industry standards

$35M
$45M
$65M
$85M
$100M

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Health Savings Account/Flexible Spending Account
  • Paid Vacation
  • Paid Holidays
  • Paid Sick Leave
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Hybrid Work Options
  • Wellness Program
  • Stock Options

Growth & Insights and Company News

6 month growth

-7%

1 year growth

58%

2 year growth

257%
Eyewire
Nov 9th, 2026
Tenpoint Therapeutics launches telehealth prescribing program for Yuvezzi.

Tenpoint Therapeutics launches telehealth prescribing program for Yuvezzi. Tenpoint Therapeutics has launched a telehealth prescribing program for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, providing adults with presbyopia an online option to determine their eligibility for a prescription treatment for presbyopia. The program connects eligible adults with an ophthalmologist or optometrist for a virtual evaluation to determine whether Yuvezzi is appropriate. Patients can access the service through orderYuvezzi.com or by calling 800-204-3511. According to Tenpoint, the initiative is intended to complement rather than replace routine in-person eye care. Participants will be encouraged to establish and maintain relationships with local eye care professionals for comprehensive examinations and ongoing eye health management. To support that effort, the company has also launched Yuvezzidoctor.com, an online resource designed to help patients locate eye care professionals in their communities. "Many adults experiencing blurry close-up vision - especially those who don't have an ophthalmologist or optometrist - may not realize that new prescription eye drops like Yuvezzi are an option to help reduce the constant need for reading glasses," said Carol Kearney, chief commercial officer of Tenpoint Therapeutics. Ms. Kearney added that the telehealth initiative is intended to expand access to treatment evaluations while reinforcing the importance of comprehensive eye care and supporting local practices. Previously known as Brimochol PF, Yuvezzi was approved by the FDA in January 2026.

The Economic Times
Aug 20th, 2026
Lupin arm to commercialise YUVEZZI eye drop across key European markets.

Lupin arm to commercialise YUVEZZI eye drop across key European markets. PTI Last Updated: Aug 20, 2026, 01:14:00 PM IST Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia. New Delhi: Pharma major Lupin Ltd on Thursday said its wholly-owned arm VISUfarma BV has entered into an exclusive licensing agreement with Visus Therapeutics Inc to commercialise YUVEZZI, an ophthalmic product indicated for the treatment of loss of clear close-up vision in adults, in specified global markets. The licensing pact with Visus Therapeutics Inc, a wholly-owned arm of Tenpoint Therapeutics Holding Ltd, provides VISUfarma exclusive rights to undertake regulatory activities, commercialisation, marketing, promotion, distribution and sale of YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, in the European Union, the UK, Switzerland, Norway and Iceland, Lupin said in a regulatory filing. You May Like Under the agreement, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus, individually or collectively, will also be eligible to receive regulatory and commercial milestone payments, as well as tiered royalties based on net sales, it added. The total potential consideration under the agreement is up to 75 million euros through to first commercial sales in the territory, the company said. It comprises a 20 million euro strategic investment in the capital stock of Visus or its parent entity through a SAFE (Simple Agreement for Future Equity) instrument, which provides the right to receive capital stock of Visus or its parent entity upon the occurrence of specified equity financing or public listing events, and up to 55 million euro in regulatory and commercial milestone payments, the filing added. In addition, the agreement provides for royalty payments based on net sales and sales milestone payments upon achievement of specified sales thresholds in the Licensed Territories, in accordance with the terms of the agreement, it added. "Building on the strategic acquisition of VISUfarma, this partnership further strengthens our vision care franchise and expands our presence across key European markets," Lupin CEO Vinita Gupta said. She further said, "The addition of YUVEZZI underscores our commitment to broadening access to differentiated therapies, improving patient outcomes, and reinforcing our leadership in eye care across the licensed territories." Tenpoint CEO Henric Bjarke said, "Lupin's strong commercial operations span major European markets, and its specialty ophthalmology company VISUfarma's long-standing presence in eyecare makes them an excellent partner. We look forward to working together as we bring YUVEZZI to Europe." The company said that, as the first and only approved once-daily, dual-agent eye drop for presbyopia, YUVEZZI represents a significant advancement in eye care. Presbyopia is a condition when eyes gradually lose the ability to see things clearly up close.

PR Newswire
Aug 20th, 2026
Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

Business Wire
Jun 29th, 2026
Tenpoint Therapeutics launches puppet-led campaign for YUVEZZI presbyopia eye drops

Tenpoint Therapeutics has launched a national consumer campaign for YUVEZZI, the first FDA-approved dual-agent, once-daily prescription eye drop for treating presbyopia. The condition affects approximately 128 million adults in the US and two billion people globally. The "Friends of the Presbyopians" campaign features hand-crafted puppets representing everyday objects like restaurant menus, smartphones and reading glasses. The puppets humorously voice frustrations about being overused as workarounds for blurry close-up vision, highlighting the daily adjustments people with presbyopia make. YUVEZZI combines carbachol and brimonidine tartrate to improve near vision. Clinical studies showed it provided up to eight continuous hours of improved close-up vision, with some patients reading three more lines on an eye chart within 30 minutes. The campaign launches nationwide across digital and social channels.

The Tifton Gazette
Apr 8th, 2026
Ritedose announces manufacturing for Tenpoint Therapeutics' presbyopia eye drop.

Ritedose announces manufacturing for Tenpoint Therapeutics' presbyopia eye drop. GlobeNewswire | The Ritedose Corporation Today at 5:34am PDT COLUMBIA, S.C., April 08, 2026 (GLOBE NEWSWIRE) - The Ritedose Corporation, Inc. (Ritedose), the largest contract development manufacturing organization (CDMO) in the United States specializing in sterile Blow-Fill-Seal (BFS) production of unit dose solutions for the ophthalmic and respiratory markets, is partnering with Tenpoint Therapeutics, Ltd. to manufacture YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop FDA-approved for the treatment of presbyopia. The selection of Ritedose as a CDMO reflects a deliberate commitment to commercial readiness and supply security. In the ophthalmic space, where validated sterile manufacturing and rigorous quality oversight are critical to earning the confidence of investors, physicians, and the broader market, partnering with a proven manufacturer is a strategic imperative. By aligning with Ritedose and its more than 25 years of experience in sterile ophthalmic and respiratory manufacturing, Tenpoint has meaningfully de-risked its production pathway and demonstrated the discipline to choose best-in-class partners in bringing YUVEZZI to patients at scale. "Our leading aseptic manufacturing capabilities make Ritedose the ideal partner to deliver safe and effective doses of YUVEZZI to patients," said Jody Chastain, president and CEO of Ritedose. "We have been serving the ophthalmic and the respiratory markets for over 25 years, and this partnership reflects what that track record means in practice. Tenpoint Therapeutics chose us - a CDMO with proven execution, supply chain security and an uncompromised standard of quality. We are proud to help Tenpoint Therapeutics bring this treatment to the patients who need it." "Ritedose is proud to work alongside Tenpoint Therapeutics on the manufacturing of national launch quantities of YUVEZZI so this treatment can be available to all presbyopia patients who need it," continued Chastain. About The Ritedose Corporation Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company's process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com. About Tenpoint Therapeutics Tenpoint Therapeutics Ltd. is a commercial-stage ophthalmic pharmaceuticals company focused on the commercialization of YUVEZZI(TM)(carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, the first and only dual-agent eye drop for the treatment of presbyopia, a condition that affects nearly 128 million people in the US and approximately two billion people globally. By understanding real-world needs and partnering with care eye professionals, Tenpoint is working to bring innovation to the aging eye. To learn more, visit tenpointtherapeutics.com and connect on LinkedIn. Media Contacts Alex Keown Inspire Agency on behalf of Ritedose [email protected] 630-346-5141 This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Recently Posted Jobs

Sign up to get curated job recommendations

Tenpoint Therapeutics is Hiring for 14 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs